| Accession | Title | Sample type | Organism(s) | Ch | Platform | Series | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|---|
 Filter
|
GSE244176
|
||||||||
| GSM7808337 |
A549 human lung carcinoma, RNaseL_KO, Rnase A, 4.5h, rep1
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM7808338 |
A549 human lung carcinoma, RNaseL_KO, BSA, 4.5h, rep1
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM7808339 |
A549 human lung carcinoma, RNaseL_KO, BSA, 4.5h, rep2
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM7808340 |
A549 human lung carcinoma, RNaseL_KO, Rnase A, 4.5h, rep2
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188695 |
A549 human lung carcinoma, WT, Lipofectamine (Control), 4.5h, 1
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188696 |
A549 human lung carcinoma, WT, 1 µM 2-5A , 4.5h, 1
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188697 |
A549 human lung carcinoma, WT, Lipofectamine (Control), 4.5h, 2
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188698 |
A549 human lung carcinoma, WT, 0.25 µg/ml poly I:C, 4.5h, 1
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188699 |
A549 human lung carcinoma, WT, Lipofectamine (Control), 4.5h, 3
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188700 |
A549 human lung carcinoma, WT, 1 µM 2-5A , 4.5h, 2
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188701 |
A549 human lung carcinoma, WT, 0.25 µg/ml poly I:C, 4.5h, 2
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188702 |
A549 human lung carcinoma, RNAseL KO, Lipofectamine (Control), 4.5h
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188703 |
A549 human lung carcinoma, RNAseL KO, 1 µM 2-5A , 4.5h
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 | |||
| GSM8188704 |
A549 human lung carcinoma, RNAseL KO, 0.25 µg/ml poly I:C, 4.5h
|
SRA | 1 |
|
Nicholas R Guydosh | Apr 30, 2024 |
